

Tipranavir

Catalog No: tcsc1210



Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg



Specifications

CAS No:

174484-41-4

Formula:

$C_{31}H_{33}F_3N_2O_5S$

Pathway:

Metabolic Enzyme/Protease;Anti-infection

Target:

HIV Protease;HIV

Purity / Grade:

>98%

Solubility:

Ethanol : ≥ 50 mg/mL (82.97 mM)

Alternative Names:

PNU-140690

Observed Molecular Weight:

602.66


Product Description

Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of **HIV-1 protease**, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with **IC₅₀s** of 66-410 nM.

IC50 & Target: IC50: 66-410 nM (HIV-1 isolates)^[1]

In Vitro: Tipranavir (PNU-140690) inhibits the enzymatic activity of HIV-1 protease, blocks the dimerization of protease subunits, and exerts potent activity against a wide spectrum of wild-type and multi-PI-resistant HIV-1 variants. When a mixture of 11 multi-PI-resistant (but TPV-sensitive) clinical isolates (HIV_{11MIX}), which include HIV_B and HIV_C, is selected against Tipranavir, HIV_{11MIX} rapidly (by 10 passages [HIV_{11MIX}^{P10}]) acquires high-level Tipranavir (PNU-140690) resistance and replicates at high concentrations of Tipranavir (PNU-140690). cHIV_B^{I54V} and cHIV_B^{I54V/V82T} are significantly resistant to Tipranavir (PNU-140690), with IC₅₀s of 2.9 and 3.2 μM, respectively, which are 11- and 12-fold increases in comparison to the IC₅₀ against cHIV_B, respectively^[1].

In Vivo: Tipranavir (PNU-140690) is administered orally twice daily and must be given in combination with low-dose ritonavir (RTV) to boost Tipranavir bioavailability. In Tipranavir/r-cotreated mice, the Tipranavir (PNU-140690) abundance in the liver, spleen, and eyes is significantly higher than that in mice treated with Tipranavir alone. Tipranavir (PNU-140690) metabolites accounts for 31 and 38% in the serum and liver in the Tipranavir-alone group. In Tipranavir (PNU-140690) and Tipranavir (TPV/r)-cotreated mice, only 1 and 2% of metabolites are detected in the serum and liver. Sprague-Dawley rats are administered a single dose of [¹⁴C]Tipranavir (PNU-140690) with coadministration of RTV. The most abundant metabolite in feces is an oxidation metabolite. In urine, no single metabolite is found to be significantly present^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!